Colon Cancer Screening

When colorectal cancer is diagnosed at an early, localized state, five-year survival is 90%, yet only 37% of incident cases are diagnosed while still localized. The same methods used to detect colorectal cancers at early, curable stages can also identify and remove adenomas, which give rise to colorectal cancer. Methods for early detection can therefore actually prevent colorectal cancer.

Definitions of Early Detection Methods are as follows:

- **Fecal Occult Blood Test (FOBT)** - FOBT is a laboratory procedure that refers to the implementation of the protocol for collecting and testing six samples from three consecutive stools at home. Prior to testing with a guaiac-based test, individuals are instructed to avoid non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen, or aspirin (more than one adult aspirin per day) for seven days prior to testing; to avoid vitamin C in excess of 250 mg from either supplements or citrus fruits and juices for three days before testing; and to avoid red meats for three days before testing.

- **Fecal immunochemical tests (FIT)** - employs the use of antibodies to detect the globin portion of human hemoglobin in stool. Because globin is degraded during passage through the upper GI tract, the FIT is specific for bleeding that is limited to the colon and rectum.

- **Digital Rectal Examination (DRE)** - DRE is part of a physical examination which refers to the palpation of the anus and lower rectum by the practitioner using a gloved finger. DRE is a method for identifying masses in the anal canal or lower rectum. A single test of a stool sample in the clinical setting (as, for instance, is often done with the stool sample collected on the fingertip during a DRE) is not an adequate substitute for the recommended procedure of collecting two samples from three consecutive specimens.

- **Flexible Sigmoidoscopy** - Flexible sigmoidoscopy refers to a surgical procedure that allows direct visual examination of the distal portion of the colorectum by a trained examiner using a flexible 60-cm endoscope following a satisfactory cleansing of the descending and sigmoid colon and rectum.

- **Colonoscopy** - Colonoscopy refers to a surgical procedure that allows direct visual examination of the entire colorectum using a colonoscope. Ideally, the colonoscopic examination should be extended to the cecum.

- **Double Contrast Barium Enema (DCBE)** - DCBE refers to a procedure that allows radiologic examination of the entire colorectum by instilling both barium and air to define the contours of the colorectal mucosa.

This guideline does not address the following:

- **Virtual Colonoscopy**. Please see policy titled, Colonoscopy, Virtual, number RAD5034.
- **Fecal DNA testing**. Please see policy titled, Genetic Testing for Colon Cancer, number MED1171.
Policy: Colon Cancer Screening

Evidence Based Guideline for Colon Cancer Screening

Colonoscopy may be appropriate for any non-symptomatic individual who is:

1. At least 50 years of age, or
2. Less than 50 years of age and at increased or high risk for colorectal cancer according to the most recently published colorectal cancer screening guidelines of the American Cancer Society or guidelines adopted by the North Carolina Advisory Committee on Cancer Coordination and Control.*

According to the American Cancer Society Guidelines on Screening and Surveillance for the Early Detection of Colorectal Adenomas and Cancer (refer to CA Cancer J Clin 2006;56;16) for average-risk women and men ages 50 and older, the following tests are recommended options for colorectal cancer screening:

- Fecal Occult Blood Test or Fecal immunochemical Test (FOBT or FIT and Flexible Sigmoidoscopy) - FOBT or FIT annually and flexible sigmoidoscopy every 5 years. Flexible sigmoidoscopy together with FOBT or FIT is preferred compared with FOBT or FIT or flexible sigmoidoscopy alone.
- Flexible Sigmoidoscopy - Every 5 years;
- Fecal Occult Blood Test or Fecal Immunochemical Test- Annually;
- Colonoscopy - Every 10 years;
- Double Contrast Barium Enema - Every 5 years.

Based on the American Cancer Society Guidelines on Screening and Surveillance for the Early Detection of Colorectal Adenomas and Cancer (refer to CA Cancer J Clin 2006;56;16), patients at increased or high risk for colorectal cancer include:

Women or men at increased risk:

- People with a single, small (less than 1 cm) adenoma. 3 - 6 years after the initial polypectomy, recommend colonoscopy. If the exam is normal, the patient can thereafter be screened as per average risk guidelines.
- People with a large (1 cm +) adenoma, multiple adenomas, or adenomas with high-grade dysplasia or villous change. Within 3 years after the initial polypectomy, recommend colonoscopy. If normal, repeat examination in 3 years; if normal then, the patient can thereafter be screened as per standard guidelines for the risk category.

- Personal history of curative-intent resection of colorectal cancer. Within 1 year after cancer resection, recommend colonoscopy. If normal, repeat examination in 3 years; if normal then, repeat examination every 5 years.
- Either colorectal cancer or adenomatous polyps, in any first-degree relative before age 60, or in two or more first-degree relatives at any age (if not a hereditary syndrome). Age 40, or 10 years before the youngest case in the immediate family, recommend colonoscopy every 5 - 10 years. Colorectal cancer in relatives more distant than first-degree does not increase risk substantially above the average risk group.
- People with a diagnosis of hereditary non-polyposis colorectal cancer (HNPCC) or those people who are at risk for HNPCC should have a colonoscopy every one-two years. It is recommended that screening should begin at the age of 20 - 25 years old or 10 years prior to the youngest family member diagnosed with colon cancer, whichever comes first.
Women or men at high risk:

- Family history of familial adenomatous polyposis (FAP) at puberty. Recommend early surveillance with endoscopy.
- Inflammatory bowel disease, chronic ulcerative colitis, crohn’s disease; cancer risk begins to be significant 8 years after the onset of pancolitis, or 12 - 15 years after the onset. Recommend colonoscopy with biopsies for dysplasia every 1 - 2 years.

Medical Evidence regarding Colon Cancer Screening indicates it is not recommended in the following situations:

- When the patient does not meet the criteria above.

Benefits Application

Please refer to certificate for availability of benefit. This guideline relates only to the services or supplies described herein. Benefits may vary according to benefit design; therefore certificate language should be reviewed before applying the terms of the policy.

This guideline addresses only colon cancer screening and does not apply to patients with signs or symptoms that may be related to diseases or conditions of the colon.

Colonoscopy and sigmoidoscopy are considered surgical procedures.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable codes: 45330, 45378, 74280, 82270, 82274, G0104, G0105, G0106, G0107, G0120, G0121, G0122, G0328

Medical Term Definitions

Not applicable

Scientific Background and Reference Sources


Policy: Colon Cancer Screening

colorect/colorec.htm 11/04/1999


*General Statutes of North Carolina enacts: Section 1. Article 51 of Chapter 58; 58-3-179 for Coverage for colorectal cancer screening.


Policy Implementation/Update Information


1/02 Policy revised to include General Statutes of North Carolina enacts: Section 1. Article 51 of Chapter 58; 58-3-179 for Coverage for colorectal cancer screening. Guidelines were taken from the American Cancer Society and the North Carolina Advisory Committee on Cancer Coordination and Control for colorectal cancer screening. Policy name changed from Colonoscopy.

3/02 Added 82274 to the Billing/Coding Section and to the System Application Guidelines.

6/02 Specialty Matched Consultant Advisory Panel. Revised the "Description" section of the policy to include FOBT as a laboratory procedure, DRE as part of a physical examination, flexible sigmoidoscopy and colonoscopy as a surgical procedure. Under "Policy Guidelines" section added the statement that colonoscopy and sigmoidoscopy are considered surgical procedures.

1/03 Codes 45355 and 45379 - 45385 removed from the Billing/Coding section of the policy. Statement added to Billing/Coding section that medical records may be ordered. System codes revised.

3/04 Benefits Application and Billing/Coding sections updated for consistency. Individual CPT codes listed for CPT code ranges G0104-G0107 under Billing/Coding section.

6/10/04 Specialty Matched Consultant Advisory Panel review. Under the section When Colon Cancer Screening is covered, A. second bullet, changed wording from "screened as per average risk guidelines" to "screened as per standard guidelines for the risk category". Removed the sentence "Medical policy will be updated as appropriate." from Policy Guidelines section. This is standard for all Medical Policy. References added. Notification 6/10/2004. Effective date 8/12/2004.
10/28/04 New HCPCS code G0328 added to policy.

5/22/06 Specialty Matched Consultant Advisory Panel review 4/20/2006. Added additional bullet under "When Covered" section "Women or Men at Increased Risk" to indicate "People with a diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) or those people who are at risk for HNPCC should have a colonoscopy every one-two years. It is recommended that screening should begin at the age of 20 - 25 years old or 10 years prior to the youngest family member diagnosed with colon cancer, whichever comes first." Added references to Fecal immunochemical test (FIT) as appropriate in the "Description of Procedure or Service" and the "When Covered" section. Updated references in policy to the American Cancer Society Guidelines for the Early Detection of Cancer, 2006. References added.

8/28/06 Medical Policy changed to Evidence Based Guideline.

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.